drugset / Trial / NCT04466670

Hemostasis in COVID-19: an Adaptive Clinical Trial

NCT04466670

Phase 2 Unknown 379 enrolled University of Sao Paulo General Hospital
RandomizedSequentialQuadruple-blindTreatment

Summary

Hypercoagulability has been demonstrated in COVID-19, leading to respiratory distress and increased mortality. This is an adaptive clinical trial to compare the efficacy and safety of two experimental strategies in patients with COVID-19: ASA or inhaled UFH associated with standard VTE prophylaxis.

Timeline

Start
2020-07-11
Primary completion
2021-12-30
Completion
2022-05-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 100 mg Oral
Subject Heparin Other / unclassified 25000 iu Inhaled

Indications